Matinas BioPharma was off by nearly 50% on data coming out of its midstage vulvovaginal candidiasis candidate.

Kala Pharmaceuticals has filed to list on Nasdaq to equip itself to file for approvals of corticosteroid nanosuspension KPI-121 in two indications.

Bluebird Bio reported encouraging data on revamped gene therapy for sickle cell disease and beta thalassemia, but shares slipped 6% premarket.

GenSight Biologics has raised €22.5 million to prepare to bring gene therapy GS010 to market in the U.S. and Europe.

Aveo Pharmaceuticals’ troubled tivozanib is on the cusp of winning approval in Europe, sending its stock on a tear.

BIO elected Alnylam CEO Maraganore as new chair, Neon tapped ex-Merrimack CFO Al-Wakeel, Biogen hired ex-Shire exec Gregory to lead human resources.

In our EuroBiotech roundup this week, Galapagos delays cystic fibrosis program, Zealand heads to phase 3 and Pluristem loses out on $30 million. 

In this week's EuroBiotech Report, J&J spins out Idorsia, Bavarian Nordic delays data, Woodford backs dementia fund and more. 

Biotech stocks are enjoying their most buoyant patch in months, after reports President Trump's crackdown on pricing may not be as tough as feared.

ElexoPharm has licensed inhibitors of the aldosterone synthase enzyme to Angion Biomedica.